Epifrontier Therapeutics
1 known investors
Find your way into Epifrontier Therapeutics
EpiFrontier Therapeutics is a biotech developing oral epigenetic drugs for beta-globin disorders, with lead candidate EPF-001, a G9a inhibitor raising fetal hemoglobin to treat sickle cell disease and beta-thalassemia.
Investors · 1
In the news
Frequently asked questions
- What does Epifrontier Therapeutics do?
- EpiFrontier Therapeutics is a biotech developing oral epigenetic drugs for beta-globin disorders, with lead candidate EPF-001, a G9a inhibitor raising fetal hemoglobin to treat sickle cell disease and beta-thalassemia.
- Who are Epifrontier Therapeutics's investors?
- Epifrontier Therapeutics's investors include UTEC.